DATE
October 30, 2025
CATEGORY
Blog
SHARE
The pharmaceutical supply chain across the Middle East and North Africa (MENA) is undergoing a fundamental recalibration. For decades, the region’s medicine shelves were stocked through foreign imports up to 80–90% of all drugs in countries like Saudi Arabia and the UAE, according to their health ministries. But the post-pandemic world, fractured logistics, and national visions for self-reliance are reshaping the rules.
From the industrial corridors of Cairo to the biotech parks of Abu Dhabi, the region is grappling with a dual challenge, securing access to advanced therapies while building resilient local ecosystems. Striking that balance between imports and domestic manufacturing is no longer just an economic consideration; it’s a question of health security, sovereignty, and long-term competitiveness.
The Current Landscape: A Region in Transition
MENA’s pharmaceutical production is expanding; but unevenly.
– The UAE is evolving into a manufacturing and innovation hub, leveraging AI-driven traceability systems and global partnerships.
– Saudi Arabia, guided by Vision 2030, is aggressively localizing biologics and specialty therapies through state-backed firms like Lifera.
– Egypt, already meeting over 90% of its domestic demand, dominates the region in production volume and is accelerating exports.
– Morocco is cultivating generics and biotech clusters to power regional exports.
– Lebanon, despite economic headwinds, sustains local manufacturing through licensed production.
– Jordan remains a pharmaceutical success story exporting nearly 80% of its output and contributing substantially to its GDP.
Together, these nations illustrate a region at a crossroads where Egypt and Jordan lead in scale, while the UAE and Saudi Arabia lead in sophistication.
Import Dependency: The Cost of Convenience
Imports remain the backbone of MENA’s medicine supply. The UAE sources innovative therapies from Europe and generics from Asia, while Saudi Arabia’s imports are largely biologics and APIs from India and China. Lebanon relies on foreign drugs for up to 80% of its needs; a vulnerability magnified by currency crashes and port disruptions.
This dependency isn’t just logistical rather it’s strategic. When 70–90% of your medicines come from abroad, supply shocks translate directly into health crises. Red Sea shipping delays, COVID-era factory shutdowns in Asia, and volatile exchange rates have all exposed the fragility of MENA’s import-heavy model.
Local Manufacturing: Stability, Sovereignty, and Strategy
Local production offers a compelling counterweight. It creates jobs, lowers costs, and safeguards supply chains. In Egypt, locally produced generics meet nearly all chronic-care needs, saving millions annually. In Jordan, domestic manufacturing fulfills half of all chronic disease demand. Meanwhile, Saudi Arabia and the UAE are channeling billions into high-value therapies like insulin, biologics, and biosimilars through smart partnerships with multinational firms.
But localization isn’t just about economics. It’s about strategic autonomy. Countries that can manufacture their own medicines are less exposed to geopolitical risk, supply disruptions, and foreign pricing pressures all of which have intensified since 2020.
Infrastructure and Digital Transformation: Building Smarter Supply Chains
The region’s logistics landscape is maturing fast.
– The UAE’s Tatmeen system and KEZAD pharma zone set global standards in drug traceability and cold-chain integrity.
– Saudi Arabia’s Sudir City pharma hub aims to centralize manufacturing and distribution under Vision 2030.
– Egypt is upgrading rural logistics and port operations to streamline exports through the Suez Canal.
– Morocco’s Tangier Med port is emerging as an export gateway to Africa.
– Lebanon’s MediTrack system sustains pharmacy-level transparency despite infrastructure strain.
– Jordan’s efficient export logistics position Amman as a key regional node.
Collectively, these developments show a region investing not only in production, but in digitalized, data-driven resilience.
Lessons from Crises: COVID-19 as Catalyst
COVID-19 was a stress test and a wake-up call. Supply halts from Asia exposed how few countries could meet even basic drug needs. Saudi Arabia’s SFDA used its real-time tracking system to avert shortages, while Egypt and Jordan leaned on local production to stabilize availability. Lebanon, by contrast, saw chronic-care drugs vanish amid economic collapse.
The lesson is clear: localization, supported by digital infrastructure, isn’t a luxury it’s a lifeline.
Government Strategies: Localization as National Policy
– UAE: Through MOHAP’s National Drug Policy, the country is courting global players like Pfizer to establish R&D hubs and AI-powered biotech plants aiming for near-self-sufficiency in essential drugs.
– Saudi Arabia: Vision 2030’s Health Sector Transformation Program targets 40% local pharma content, supported by SFDA’s digital tracking and PIF-funded biologics initiatives.
– Egypt: With 93% local coverage, new API plants, and rising exports, Egypt is positioning itself as Africa’s leading pharma producer.
– Morocco: Focused on generics, biotech, and export-oriented industrial clusters, aligning industrial and health reforms.
Localization policies are no longer pilot projects they’re national missions that intertwine economic diversification, job creation, and health sovereignty.
The Payoff: Economic and Strategic Benefits
The numbers speak volumes.
– Jordan’s pharma sector employs over 10,000 people and contributes 4% to GDP.
– Locally produced drugs are typically 30–50% cheaper than imports.
– Egypt’s EGP 300 billion market demonstrates the fiscal upside of domestic supply.
– Saudi and UAE factories are emerging as regional export engines, with AI-enabled production lines and eco-certified facilities.
Beyond economics, local manufacturing enhances supply security, builds regional expertise, and reduces vulnerability to global disruptions. The more MENA nations produce locally, the less they’ll pay in both currency and crisis costs.
The Road Ahead: Collaboration and Harmonization
Despite progress, challenges remain fragmented regulations, limited API capacity, and skill shortages. Regional alignment on GMP standards, workforce training, and R&D investment could close these gaps.
Collaboration is the next frontier.
Arab Pharma and cross-border alliances can harmonize standards, share technology, and foster scale. Morocco’s export partnerships in Africa and Saudi-UAE innovation clusters are early signs of regional cohesion.
Conclusion: From Dependency to Resilience
The MENA pharmaceutical industry stands at a pivotal juncture. What began as a conversation about self-reliance has evolved into a movement toward sustainable, tech-enabled independence.
Initiatives like Saudi Vision 2030, UAE’s biotech acceleration, and Egypt’s API expansion are redefining how and where medicines are made.
The path forward demands balance: retain essential imports for innovation, but build domestic muscle for security. If executed strategically, MENA could transform from an import-reliant consumer into a globally recognized producer a region where resilience, innovation, and access converge.
